Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

VERBATIM (per left-bucket scout, contiguous paragraphs 1-3 + non-contiguous fragments):

"Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma."

"The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans."

"In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed."

Non-contiguous verbatim fragments:
- "The Food and Drug Administration has not yet approved the vaccine."
- Dr. Ahmad Tarhini (H. Lee Moffitt Cancer Center): "It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself."
- Dr. Tarhini: "I think it will certainly improve the outcome of our patients. We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."
- Phase 2b context (truncated at 125 chars by fetch tool): "In Phase 2b trials, the treatment showed a 49% reduction of melanoma return... and a 59% reduction of metastasization..." (the 59% refers to cancer spreading to distant organs).
- "Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators..." (fragment).

AUDIT NOTE: ABC's headline is hedged ("shows promise in extending lifespan") versus CNN's definitive "succeeded." ABC flags the FDA has not yet approved the vaccine. Per the fetch, ABC's article does NOT mention the stock reaction, does NOT mention Trump-administration mRNA pushback, and does NOT explicitly state that overall-survival results are pending.